Galectin binding to neo-glycoproteins: LacDiNAc conjugated BSA as ligand for human galectin-3

Biomolecules

Volumn 5, Issue 3, 2015, Pages 1671-1696

  Böcker, Sophia ^a   Laaf, Dominic ^a   Elling, Lothar ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Chemo enzymatic synthesis; Galectin 3; LacDiNAc; Multivalency; Neo glycoproteins

Indexed keywords

BOVINE SERUM ALBUMIN; GALECTIN; GALECTIN 3; LACDINAC LIGAND; LIGAND; NEOGLYCOPROTEIN; UNCLASSIFIED DRUG; GALECTIN 1; GLYCOPROTEIN; LACTOSE; N-ACETYLGALACTOSAMINYL-1-4-N-ACETYLGLUCOSAMINE; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CROSS LINKING; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNE RESPONSE; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BOVINE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR MODEL; SYNTHESIS;

BOVINAE;

ANIMALS; CARBOHYDRATE CONFORMATION; CATTLE; GALECTIN 1; GALECTIN 3; GLYCOPROTEINS; HUMANS; LACTOSE; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; SERUM ALBUMIN, BOVINE;

EID: 85012053595     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5031671     Document Type: Article

References (107)

1. Varki, A. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 1993, 3, 97-130.
2. Zhao, Y.-Y.; Takahashi, M.; Gu, J.-G.; Miyoshi, E.; Matsumoto, A.; Kitazume, S.; Taniguchi, N. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci. 2008, 99, 1304-1310.
3. Boscher, C.; Dennis, J.W.; Nabi, I.R. Glycosylation, galectins and cellular signaling. Curr. Opin. Cell Biol. 2011, 23, 383-392.
4. Fred Brewer, C. Binding and cross-linking properties of galectins. BBA Gen. Subj. 2002, 1572, 255-262.
5. Funasaka, T.; Raz, A.; Nangia-Makker, P. Galectin-3 in angiogenesis and metastasis. Glycobiology 2014, 24, 886-891.
6. Lau, K.S.; Dennis, J.W. N-glycans in cancer progression. Glycobiology 2008, 18, 750-760.
7. Noorjahan, P. Role of galectins in wound healing. In Galectins and Disease Implications for Targeted Therapeutics; ACS: Washington, DC, USA, 2012; Volume 1115, pp. 415-432.
8. Schattner, M. Platelets and galectins. Ann. Transl. Med. 2014, 2, doi:10.3978/j.issn.2305-5839.2014.09.02.
9. Lundquist, J.J.; Toone, E.J. The cluster glycoside effect. Chem. Rev. 2002, 102, 555-578.
10. Kiessling, L.L.; Young, T.; Gruber, T.D.; Mortell, K.H. Multivalency in protein-carbohydrate recognition. In Glycoscience; Fraser-Reid, B., Tatsuta, K., Thiem, J., Eds.; Springer: Berlin, Heidelberg, Germany, 2008; pp. 2483-2523.
11. Pieters, R.J. Maximising multivalency effects in protein-carbohydrate interactions. Org. Biomol. Chem. 2009, 7, 2013-2025.
12. Pieters, R.J.; Arnusch, C.J.; Breukink, E. Membrane permeabilization by multivalent anti-microbial peptides. Protein Pept. Lett. 2009, 16, 736-742.
13. Bernardi, A.; Jimenez-Barbero, J.; Casnati, A.; de Castro, C.; Darbre, T.; Fieschi, F.; Finne, J.; Funken, H.; Jaeger, K.-E.; Lahmann, M., et al. Multivalent glycoconjugates as anti-pathogenic agents. Chem. Soc. Rev. 2013, 42, 4709-4727.
14. Peri, F. Clustered carbohydrates in synthetic vaccines. Chem. Soc. Rev. 2013, 42, 4543-4556.
15. Branson, T.R.; Turnbull, W.B. Bacterial toxin inhibitors based on multivalent scaffolds. Chem. Soc. Rev. 2013, 42, 4613-4622.
16. Chabre, Y.M.; Roy, R. Multivalent glycoconjugate syntheses and applications using aromatic scaffolds. Chem. Soc. Rev. 2013, 42, 4657-4708.
17. Marradi, M.; Chiodo, F.; Garcia, I.; Penades, S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem. Soc. Rev. 2013, 42, 4728-4745.
18. Martinez, A.; Ortiz Mellet, C.; Garcia Fernandez, J.M. Cyclodextrin-based multivalent glycodisplays: Covalent and supramolecular conjugates to assess carbohydrate-protein interactions. Chem. Soc. Rev. 2013, 42, 4746-4773.
19. Hatano, K.; Matsuoka, K.; Terunuma, D. Carbosilane glycodendrimers. Chem. Soc. Rev. 2013, 42, 4574-4598.
20. Chen, Y.; Star, A.; Vidal, S. Sweet carbon nanostructures: Carbohydrate conjugates with carbon nanotubes and graphene and their applications. Chem. Soc. Rev. 2013, 42, 4532-4542.
21. Kennedy, D.C.; Grünstein, D.; Lai, C.-H.; Seeberger, P.H. Glycosylated nanoscale surfaces: Preparation and applications in medicine and molecular biology. Chem. Eur. J. 2013, 19, 3794-3800.
22. Sansone, F.; Casnati, A. Multivalent glycocalixarenes for recognition of biological macromolecules: Glycocalyx mimics capable of multitasking. Chem. Soc. Rev. 2013, 42, 4623-4639.
23. Cecioni, S.; Imberty, A.; Vidal, S. Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem. Rev. 2014, 115, 525-561.
24. Bojarová, P.; Rosencrantz, R.R.; Elling, L.; Ken, V. Enzymatic glycosylation of multivalent scaffolds. Chem. Soc. Rev. 2013, 42, 4774-4797.
25. Ercolani, G.; Schiaffino, L. Allosteric, chelate, and interannular cooperativity: A mise AU point. Angew. Chem. Int. Ed. 2011, 50, 1762-1768.
26. Hunter, C.A.; Anderson, H.L. What is cooperativity? Angew. Chem. Int. Ed. 2009, 48, 7488-7499.
27. Maierhofer, C.; Rohmer, K.; Wittmann, V. Probing multivalent carbohydrate-lectin interactions by an enzyme-linked lectin assay employing covalently immobilized carbohydrates. Bioorg. Med. Chem. 2007, 15, 7661-7676.
28. Lee, R.; Lee, Y. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconj. J. 2000, 17, 543-551.
29. Profit, A.A.; Lee, T.R.; Lawrence, D.S. Bivalent inhibitors of protein tyrosine kinases. J. Am. Chem. Soc. 1999, 121, 280-283.
30. Schaschke, N.; Matschiner, G.; Zettl, F.; Marquardt, U.; Bergner, A.; Bode, W.; Sommerhoff, C.P.; Moroder, L. Bivalent inhibition of human tryptase. Chem. Biol. 2001, 8, 313-327.
31. Rao, J.; Lahiri, J.; Isaacs, L.; Weis, R.M.; Whitesides, G.M. A trivalent system from vancomycin· d-Ala-d-Ala with higher affinity than avidin·biotin. Science 1998, 280, 708-711.
32. Blackmore, P.F.; Eisoldt, S. The neoglycoprotein mannose-bovine serum albumin, but not progesterone, activates T-type calcium channels in human spermatozoa. Mol. Hum. Reprod. 1999, 5, 498-506.
33. Oh, Y.S.; Ahn, H.S.; Gye, M.C. Fucosyl neoglycoprotein binds to mouse epididymal spermatozoa and inhibits sperm binding to the egg zona pellucida. Andrologia 2013, 45, 363-368.
34. Huang, B.X.; Kim, H.-Y.; Dass, C. Probing three-dimensional structure of bovine serum albumin by chemical cross-linking and mass spectrometry. J. Am. Soc. Mass Spectrom. 2004, 15, 1237-1247.
35. Luyai, A.; Lasanajak, Y.; Smith, D.F.; Cummings, R.D.; Song, X. Facile preparation of fluorescent neoglycoproteins using p-nitrophenyl anthranilate as a heterobifunctional linker. Bioconjug. Chem. 2009, 20, 1618-1624.
36. Unverzagt, C.; André, S.; Seifert, J.; Kojima, S.; Fink, C.; Srikrishna, G.; Freeze, H.; Kayser, K.; Gabius, H.-J. Structure-activity profiles of complex biantennary glycans with core fucosylation and with/without additional α 2,3/α2,6 sialylation: Synthesis of neoglycoproteins and their properties in lectin assays, cell binding, and organ uptake. J. Med. Chem. 2002, 45, 478-491.
37. Gabius, H.J.; Bardosi, A. Neoglycoproteins as tools in glycohistochemistry. Prog. Histochem. Cytochem. 1991, 22, 1-63.
38. Stowell, C.P.; Lee, Y.C. Neoglycoproteins the preparation and application of synthetic glycoproteins. In Advances in Carbohydrate Chemistry and Biochemistry; Tipson, R.S., Derek, H., Eds.; Academic Press: Waltham, MA, USA, 1980; Volume 37, pp. 225-281.
39. Kerekgyarto, M.; Fekete, A.; Szurmai, Z.; Kerekgyarto, J.; Takacs, L.; Kurucz, I.; Guttman, A. Neoglycoproteins as carbohydrate antigens: Synthesis, analysis, and polyclonal antibody response. Electrophoresis 2013, 34, 2379-2386.
40. Barondes, S.H.; Cooper, D.N.; Gitt, M.A.; Leffler, H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 1994, 269, 20807-20810.
41. Leffler, H.; Carlsson, S.; Hedlund, M.; Qian, Y.; Poirier, F. Introduction to galectins. Glycoconj. J. 2002, 19, 433-440.
42. Griffioen, A.W.; Thijssen, V.L. Galectins in tumor angiogenesis. Ann. Transl. Med. 2014, 2, doi:10.3978/j.issn.2305-5839.2014.09.01.
43. Rabinovich, G.A.; van Kooyk, Y.; Cobb, B.A. Glycobiology of immune responses. Ann. NY Acad. Sci. 2012, 1253, 1-15.
44. Liu, F.-T.; Rabinovich, G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5, 29-41.
45. D’Haene, N.; Maris, C.; Rorive, S.; Decaestecker, C.; le Mercier, M.; Salmon, I. Galectins and neovascularization in central nervous system tumors. Glycobiology 2014, 24, 892-898.
46. Compagno, D.; Gentilini, L.D.; Jaworski, F.M.; Pérez, I.G.; Contrufo, G.; Laderach, D.J. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology 2014, 24, 899-906.
47. Le Mercier, M.; Fortin, S.; Mathieu, V.; Kiss, R.; Lefranc, F. Galectins and gliomas. Brain Pathol. 2010, 20, 17-27.
48. Nakahara, S.; Oka, N.; Raz, A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10, 267-275.
49. Dumic, J.; Dabelic, S.; Flögel, M. Galectin-3: An open-ended story. BBA Gen. Subj. 2006, 1760, 616-635.
50. Pugliese, G.; Iacobini, C.; Pesce, C.M.; Menini, S. Galectin-3: An emerging all-out player in metabolic disorders and their complications. Glycobiology 2015, 25, 136-150.
51. Hakon, L.; Ulf, J.N. Low-molecular weight inhibitors of galectins. In Galectins and Disease Implications for Targeted Therapeutics; ACS: Washington, DC, USA, 2012; Volume 1115, pp. 47-59.
52. Stowell, S.R.; Arthur, C.M.; Mehta, P.; Slanina, K.A.; Blixt, O.; Leffler, H.; Smith, D.F.; Cummings, R.D. Galectin-1,-2, and-3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem. 2008, 283, 10109-10123.
53. Téllez-Sanz, R.; Garcia-Fuentes, L.; Vargas-Berenguel, A. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr. Med. Chem. 2013, 20, 2979-2990.
54. Ahmad, N.; Gabius, H.J.; Andre, S.; Kaltner, H.; Sabesan, S.; Roy, R.; Liu, B.C.; Macaluso, F.; Brewer, C.F. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 2004, 279, 10841-10847.
55. Lepur, A.; Salomonsson, E.; Nilsson, U.J.; Leffler, H. Ligand induced galectin-3 protein self-association. J. Biol. Chem. 2012, 287, 21751-21756.
56. Dam, T.K.; Gabius, H.-J.; André, S.; Kaltner, H.; Lensch, M.; Brewer, C.F. Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants. Biochemistry 2005, 44, 12564-12571.
57. Goodman, C.K.; Wolfenden, M.L.; Nangia-Makker, P.; Michel, A.K.; Raz, A.; Cloninger, M.J. Multivalent scaffolds induce galectin-3 aggregation into nanoparticles. Beilstein J. Org. Chem. 2014, 10, 1570-1577.
58. Yang, Y.; Xue, X.C.; Jin, X.F.; Wang, L.J.; Sha, Y.L.; Li, Z.J. Synthesis of multivalent n-acetyl lactosamine modified quantum dots for the study of carbohydrate and galectin-3 interactions. Tetrahedron 2012, 68, 7148-7154.
59. Wolfenden, M.; Cousin, J.; Nangia-Makker, P.; Raz, A.; Cloninger, M. Glycodendrimers and modified elisas: Tools to elucidate multivalent interactions of galectins 1 and 3. Molecules 2015, 20, 7059-7096.
60. Van den Berg, T.K.; Honing, H.; Franke, N.; van Remoortere, A.; Schiphorst, W.; Liu, F.T.; Deelder, A.M.; Cummings, R.D.; Hokke, C.H.; van Die, I. Lacdinac-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. J. Immunol. 2004, 173, 1902-1907.
61. Hirano, K.; Matsuda, A.; Shirai, T.; Furukawa, K. Expression of lacdinac group on N-glycans among human tumors is complex. Biomed. Res. Int. 2014, doi:10.1155/2014/981627.
62. Do, K.-Y.; Do, S.; Cummings, R.D. Differential expression of lacdinac sequences (GalNAc1-4GlcNAc-R) in glycoproteins synthesized by chinese hamster ovary and human 293 cells. Glycobiology 1997, 7, 183-194.
63. Kenny, D.T.; Skoog, E.C.; Lindén, S.K.; Struwe, W.B.; Rudd, P.M.; Karlsson, N.G. Presence of terminal N-acetylgalactosamine_1-4N-acetylglucosamine residues on O-linked oligosaccharides from gastric MUC5AC: Involvement in helicobacter pylori colonization? Glycobiology 2012, 22, 1077-1085.
64. Rossez, Y.; Gosset, P.; Boneca, I.G.; Magalhaes, A.; Ecobichon, C.; Reis, C.A.; Cieniewski-Bernard, C.; Joncquel Chevalier Curt, M.; Leonard, R.; Maes, E., et al. The lacdinac-specific adhesin laba mediates adhesion of helicobacter pylori to human gastric mucosa. J. Infect. Dis. 2014, 210, 1286-1295.
65. Šimonová, A.; Kupper, C.E.; Böcker, S.; Müller, A.; Hofbauerová, K.; Pelantová, H.; Elling, L.; Ken, V.; Bojarová, P. Chemo-enzymatic synthesis of lacdinac dimers of varying length as novel galectin ligands. J. Mol. Catal. B Enzym. 2014, 101, 47-55.
66. Kupper, C.E.; Böcker, S.; Liu, H.L.; Adamzyk, C.; van de Kamp, J.; Recker, T.; Lethaus, B.; Jahnen-Dechent, W.; Neuss, S.; Müller-Newen, G., et al. Fluorescent SNAP-Tag galectin fusion proteins as novel tools in glycobiology. Curr. Pharm. Des. 2013, 19, 5457-5467.
67. Rech, C.; Rosencrantz, R.R.; K_enek, K.; Pelantová, H.; Bojarová, P.; Römer, C.E.; Hanisch, F.-G.; K_en, V.; Elling, L. Combinatorial one-pot synthesis of poly-N-acetyllactosamine oligosaccharides with leloir-glycosyltransferases. Adv. Synth. Catal. 2011, 353, 2492-2500.
68. Kamath, V.P.; Diedrich, P.; Hindsgaul, O. Use of diethyl squarate for the coupling of oligosaccharide amines to carrier proteins and characterization of the resulting neoglycoproteins by MALDI-TOF mass spectrometry. Glycoconj. J. 1996, 13, 315-319.
69. Tietze, L.F.; Arlt, M.; Beller, M.; gl üsenkamp, K.-H.; Jähde, E.; Rajewsky, M.F. Anticancer agents, 15. Squaric acid diethyl ester: A new coupling reagent for the formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides and diamides. Chem. Ber. 1991, 124, 1215-1221.
70. Tietze, L.F.; Schroeter, C.; Gabius, S.; Brinck, U.; Goerlach-Graw, A.; Gabius, H.J. Conjugation of p-aminophenyl glycosides with squaric acid diester to a carrier protein and the use of the neoglycoprotein in the histochemical detection of lectins. Bioconjug. Chem. 1991, 2, 148-153.
71. Wang, J.W.; Asnani, A.; Auzanneau, F.I. Synthesis of a BSA-Lex glycoconjugate and recognition of Lex analogues by the anti-Lex monoclonal antibody sh1: The identification of a non-cross reactive analogue. Bioorg. Med. Chem. 2010, 18, 7174-7185.
72. Wurm, F.R.; Klok, H.A. Be squared: Expanding the horizon of squaric acid-mediated conjugations. Chem. Soc. Rev. 2013, 42, 8220-8236.
73. Komarova, B.S.; Orekhova, M.V.; Tsvetkov, Y.E.; Beau, R.; Aimanianda, V.; Latge, J.P.; Nifantiev, N.E. Synthesis of a pentasaccharide and neoglycoconjugates related to fungal alpha-(1α3)-glucan and their use in the generation of antibodies to trace aspergillus fumigatus cell wall. Chemistry 2015, 21, 1029-1035.
74. Jahouh, F.; Hou, S.J.; Kovac, P.; Banoub, J.H. Determination of glycation sites by tandem mass spectrometry in a synthetic lactose-bovine serum albumin conjugate, a vaccine model prepared by dialkyl squarate chemistry. Rapid. Commun. Mass Spectrom. 2012, 26, 749-758.
75. Jahouh, F.; Xu, P.; Vann, W.F.; Kovac, P.; Banoub, J.H. Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of vibrio cholerae, serotype ogawa and the recombinant tetanus toxin C-fragment carrier. J. Mass Spectrom. 2013, 48, 1083-1090.
76. Sauerzapfe, B.; Namdjou, D.J.; Schumacher, T.; Linden, N.; Kenek, K.; Ken, V.; Elling, L. Characterization of recombinant fusion constructs of human _1,4-galactosyltransferase 1 and the lipase pre-propeptide from staphylococcus hyicus. J. Mol. Catal. B Enzym. 2008, 50, 128-140.
77. Logan, S.M.; Altman, E.; Mykytczuk, O.; Brisson, J.R.; Chandan, V.; Schur, M.J.; St Michael, F.; Masson, A.; Leclerc, S.; Hiratsuka, K., et al. Novel biosynthetic functions of lipopolysaccharide rfaj homologs from helicobacter pylori. Glycobiology 2005, 15, 721-733.
78. Kupper, C.E.; Rosencrantz, R.R.; Henssen, B.; Pelantová, H.; Thönes, S.; Drozdova, A.; Ken, V.; Elling, L. Chemo-enzymatic modification of poly-N-acetyllactosamine (LacNAc) oligomers and N,N-diacetyllactosamine (LacDINAc) based on galactose oxidase treatment. Beilstein J. Org. Chem. 2012, 8, 712-725.
79. Hou, S.J.; Saksena, R.; Kovac, P. Preparation of glycoconjugates by dialkyl squarate chemistry revisited. Carbohydr. Res. 2008, 343, 196-210.
80. Cayot, P.; Tainturier, G. The quantification of protein amino groups by the trinitrobenzenesulfonic acid method: A reexamination. Anal. Biochem. 1997, 249, 184-200.
81. Roth, Z.; Yehezkel, G.; Khalaila, I. Identification and quantification of protein glycosylation. Int. J. Carbohydr. Chem. 2012, doi:10.1155/2012/640923.
82. Ahmad, N.; Gabius, H.J.; Kaltner, H.; Andre, S.; Kuwabara, I.; Liu, F.T.; Oscarson, S.; Norberg, T.; Brewer, C.F. Thermodynamic binding studies of cell surface carbohydrate epitopes to galectins-1,-3, and-7: Evidence for differential binding specificities. Can. J. Chem. 2002, 80, 1096-1104.
83. Rapoport, E.M.; Andre, S.; Kurmyshkina, O.V.; Pochechueva, T.V.; Severov, V.V.; Pazynina, G.V.; Gabius, H.J.; Bovin, N.V. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: A case study on galectins-1 and-3 and the impact of assay setting. Glycobiology 2008, 18, 315-324.
84. Stowell, S.R.; Dias-Baruffi, M.; Penttila, L.; Renkonen, O.; Nyame, A.K.; Cummings, R.D. Human galectin-1 recognition of poly-N-acetyllactosamine and chimeric polysaccharides. Glycobiology 2004, 14, 157-167.
85. Leppänen, A.; Stowell, S.; Blixt, O.; Cummings, R.D. Dimeric galectin-1 binds with high affinity to alpha 2,3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J. Biol. Chem. 2005, 280, 5549-5562.
86. Di Virgilio, S.; Glushka, J.; Moremen, K.; Pierce, M. Enzymatic synthesis of natural and C-13 enriched linear poly-N-acetyllactosamines as ligands for galectin-1. Glycobiology 1999, 9, 353-364.
87. Qun, Z.; Cummings, R.D. L-14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch. Biochem. Biophys. 1993, 300, 6-17.
88. Wang, H.; Huang, W.; Orwenyo, J.; Banerjee, A.; Vasta, G.R.; Wang, L.X. Design and synthesis of glycoprotein-based multivalent glyco-ligands for influenza hemagglutinin and human galectin-3. Bioorg. Med. Chem. 2013, 21, 2037-2044.
89. André, S.; Sansone, F.; Kaltner, H.; Casnati, A.; Kopitz, J.; Gabius, H.J.; Ungaro, R. Calix N arene-based glycoclusters: Bioactivity of thiourea-linked galactose/lactose moieties as inhibitors of binding of medically relevant lectins to a glycoprotein and cell-surface glycoconjugates and selectivity among human adhesion/growth-regulatory galectins. ChemBioChem 2008, 9, 1649-1661.
90. André, S.; Grandjean, C.; Gautier, F.M.; Bernardi, S.; Sansone, F.; Gabius, H.J.; Ungaro, R. Combining carbohydrate substitutions at bioinspired positions with multivalent presentation towards optimising lectin inhibitors: Case study with calixarenes. Chem. Commun. 2011, 47, 6126-6128.
91. André, S.; Pieters, R.J.; Vrasidas, I.; Kaltner, H.; Kuwabara, I.; Liu, F.T.; Liskamp, R.M.; Gabius, H.J. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. ChemBioChem 2001, 2, 822-830.
92. Song, L.; Tang, J.W.; Owusu, L.; Sun, M.Z.; Wu, J.; Zhang, J. Galectin-3 in cancer. Clin. Chim. Acta 2014, 431, 185-191.
93. Saussez, S.; Lorfevre, F.; Lequeux, T.; Laurent, G.; Chantrain, G.; Vertongen, F.; Toubeau, G.R.; Decaestecker, C.; Kiss, R. The determination of the levels of circulating galectin-1 and α-3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral. Oncol. 2008, 44, 86-93.
94. Sakaki, M.; Oka, N.; Nakanishi, R.; Yamaguchi, K.; Fukumori, T.; Kanayama, H.O. Serum level of galectin-3 in human bladder cancer. J. Med. Invest. 2008, 55, 127-132.
95. Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; Iacobelli, S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 2000, 6, 1389-1393.
96. Johnson, K.D.; Glinskii, O.V.; Mossine, V.V.; Turk, J.R.; Mawhinney, T.P.; Anthony, D.C.; Henry, C.J.; Huxley, V.H.; Glinsky, G.V.; Pienta, K.J., et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007, 9, 662-670.
97. Sörme, P.; Arnoux, P.; Kahl-Knutsson, B.; Leffler, H.; Rini, J.M.; Nilsson, U.J. Structural and thermodynamic studies on cation-Pi interactions in lectin-ligand complexes: High-affinity galectin-3 inhibitors through fine-tuning of an arginine-arene interaction. J. Am. Chem. Soc. 2005, 127, 1737-1743.
98. Nangia-Makker, P.; Hogan, V.; Honjo, Y.; Baccarini, S.; Tait, L.; Bresalier, R.; Raz, A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J. Natl. Cancer Inst. 2002, 94, 1854-1862.
99. Iurisci, I.; Cumashi, A.; Sherman, A.A.; Tsvetkov, Y.E.; Tinari, N.; Piccolo, E.; D’Egidio, M.; Adamo, V.; Natoli, C.; Rabinovich, G.A., et al. Synthetic inhibitors of galectin-1 and α-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 2009, 29, 403-410.
100. Michel, A.K.; Nangia-Makker, P.; Raz, A.; Cloninger, M.J. Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/muc1 mediated cancer cellular aggregation. ChemBioChem 2014, 15, 2106-2112.
101. Prasanphanich, N.S.; Song, X.; Heimburg-Molinaro, J.; Luyai, A.E.; Lasanajak, Y.; Cutler, C.E.; Smith, D.F.; Cummings, R.D. Intact reducing glycan promotes the specific immune response to lacto-n-neotetraose-bsa neoglycoconjugates. Bioconjug. Chem. 2015, 26, 559-571.
102. Mencke, A.J.; Wold, F. Neoglycoproteins. Preparation and in vivo clearance of serum albumin derivatives containing ovalbumin oligosaccharides. J. Biol. Chem. 1982, 257, 14799-14805.
103. Vrasidas, I.; Andre, S.; Valentini, P.; Bock, C.; Lensch, M.; Kaltner, H.; Liskamp, R.M.; Gabius, H.J.; Pieters, R.J. Rigidified multivalent lactose molecules and their interactions with mammalian galectins: A route to selective inhibitors. Org. Biomol. Chem. 2003, 1, 803-810.
104. Parera Pera, N.; Branderhorst, H.M.; Kooij, R.; Maierhofer, C.; van der Kaaden, M.; Liskamp, R.M.; Wittmann, V.; Ruijtenbeek, R.; Pieters, R.J. Rapid screening of lectins for multivalency effects with a glycodendrimer microarray. ChemBioChem 2010, 11, 1896-1904.
105. Sauerzapfe, B.; Krenek, K.; Schmiedel, J.; Wakarchuk, W.W.; Pelantova, H.; Kren, V.; Elling, L. Chemo-enzymatic synthesis of poly-N-acetyllactosamine (poly-LacNAc) structures and their characterization for CGL2-galectin-mediated binding of ecm glycoproteins to biomaterial surfaces. Glycoconj. J. 2009, 26, 141-159.
106. Chen, R.F. Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem. 1967, 242, 173-181.
107. Witten, K.G.; Rech, C.; Eckert, T.; Charrak, S.; Richtering, W.; Elling, L.; Simon, U. Glyco-DNA-gold nanoparticles: Lectin-mediated assembly and dual-stimuli response. Small 2011, 7, 1954-1960.